Trials / Completed
CompletedNCT02741310
Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex™) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study was to assess the effects of subcutaneous sumatriptan alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan concomitant therapy on resting blood pressure in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered by intravenous infusion |
| DRUG | Sumatriptan | Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5 |
| DRUG | Erenumab | Administered by intravenous infusion |
Timeline
- Start date
- 2016-02-22
- Primary completion
- 2016-08-11
- Completion
- 2016-08-11
- First posted
- 2016-04-18
- Last updated
- 2019-04-02
- Results posted
- 2019-03-05
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02741310. Inclusion in this directory is not an endorsement.